Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Saturday morning. The firm issued a sell rating on the stock.

Oragenics Stock Performance

NYSE OGEN opened at $0.33 on Friday. The company has a market capitalization of $4.03 million, a PE ratio of -0.05 and a beta of 0.43. Oragenics has a 52-week low of $0.25 and a 52-week high of $7.74. The company has a 50-day simple moving average of $0.33 and a 200 day simple moving average of $0.82.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.